POZ Community Forums
Meds, Mind, Body & Benefits => Questions About Treatment & Side Effects => Topic started by: Ihavehope on March 12, 2007, 11:14:27 am
-
Integrase inhibitors continue to be the most exciting agents in the new armamentarium for the treatment of HIV infection. During the past few conferences we have viewed the results of several studies on two compounds that have progressively advanced in clinical development. One of them, Merck 0518, now known as raltegravir (MK-0518, Isentress), is currently in phase III development and has recently become part of an expanded access program for antiretroviral-experienced patients. The preliminary results of raltegravir's phase III study, also conducted in treatment-experienced patients, were revealed for the first time at this conference.
http://thebody.com/confs/retro2007/dejesus2.html